AP Biosciences, Inc.(TW:6945)
NT$117.50+2.50 (+2.17%)
TW:6945
AP Biosciences, Inc. financials statements
NT$117.50
At close:+2.50 (+2.17%)
AP Biosciences, Inc. (6945) Ratios
AP Biosciences, Inc. Ratios
TW:6945's free cash flow for Q2 2026 was NT$-183.48M. For the 2026 fiscal year, TW:6945's free cash flow was decreased by NT$-5.29M and operating cash flow was NT$-108.06M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 29.94 | 39.87 | 24.80 | 242.10 | 26.67 |
| Quick Ratio | 29.94 | 39.87 | 24.80 | 242.10 | 26.67 |
| Cash Ratio | 23.80 | 36.34 | 9.02 | 231.91 | 24.93 |
| Solvency Ratio | -4.45 | -3.88 | -3.06 | -61.93 | -8.45 |
| Operating Cash Flow Ratio | -8.63 | -9.02 | -9.64 | -61.07 | -7.98 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | NT$ 1.13B | NT$ 1.48B | NT$ 658.99M | NT$ 1.09B | NT$ 542.80M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.04 | 0.04 | 0.09 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.05 | 0.04 | 0.10 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.04 | 0.04 | 0.09 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.07 | 1.06 | 1.14 | 1.00 | 1.04 |
| Debt Service Coverage Ratio | -302.57 | -244.91 | -270.58 | 0.00 | 0.00 |
| Interest Coverage Ratio | -320.49 | -266.42 | -288.84 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.72 | 0.96 | 1.29 | 0.00 | 0.00 |
| Net Debt to EBITDA | 2.12 | 3.40 | 0.60 | 3.61 | 2.96 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 100.00% | 0.00% | 100.00% |
| EBIT Margin | 0.00% | 0.00% | -1048.25% | 0.00% | -2670.06% |
| EBITDA Margin | 0.00% | 0.00% | -1009.25% | 0.00% | -2543.39% |
| Operating Profit Margin | 0.00% | 0.00% | -1077.35% | 0.00% | -2670.06% |
| Pretax Profit Margin | 0.00% | 0.00% | -1051.98% | 0.00% | -2682.77% |
| Net Profit Margin | 0.00% | 0.00% | -1051.98% | 0.00% | -2682.77% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | -1051.98% | 0.00% | -2682.77% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 97.46% | 96.29% | 97.65% | 100.00% | 100.48% |
| Return on Assets (ROA) | -32.58% | -24.48% | -38.09% | -26.15% | -32.38% |
| Return on Equity (ROE) | -34.99% | -26.05% | -43.27% | -26.26% | -33.61% |
| Return on Capital Employed (ROCE) | -34.46% | -26.02% | -40.41% | -26.26% | -33.45% |
| Return on Invested Capital (ROIC) | -34.16% | -25.84% | -39.87% | -26.26% | -33.45% |
| Return on Tangible Assets | -32.65% | -24.53% | -38.27% | -26.28% | -32.71% |
| Earnings Yield | -2.91% | -11.29% | -10.99% | -6.95% | -4.93% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 12.31 | 0.00 | 411.35 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.28 | 0.00 | 0.79 |
| Asset Turnover | 0.00 | 0.00 | 0.04 | 0.00 | 0.01 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.04 | 0.00 | 0.03 |
| Cash Conversion Cycle | 0.00 | 0.00 | 29.66 | 0.00 | 0.89 |
| Days of Sales Outstanding | 0.00 | 0.00 | 29.66 | 0.00 | 0.89 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 29.66 | 0.00 | 0.89 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -4.14 | -4.75 | -4.60 | -5.24 | -3.50 |
| Free Cash Flow Per Share | -4.44 | -4.83 | -5.14 | -5.29 | -3.60 |
| Dividend Paid and CapEx Coverage Ratio | -13.94 | -64.72 | -8.40 | -113.38 | -34.33 |
| Capital Expenditure Coverage Ratio | -13.94 | -64.72 | -8.40 | -113.38 | -34.33 |
| Operating Cash Flow Coverage Ratio | -5.92 | -5.05 | -3.63 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | -9.23 | 0.00 | -24.12 |
| Free Cash Flow Yield | -2.47% | -9.70% | -10.78% | -6.70% | -4.56% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -34.42 | -8.87 | -9.10 | -14.40 | -20.28 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 95.76 | 0.00 | 544.19 |
| Price-to-Book (P/B) Ratio | 12.04 | 2.31 | 3.94 | 3.78 | 6.82 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -40.57 | -10.31 | -9.27 | -14.92 | -21.92 |
| Price-to-Operating Cash Flow Ratio | -43.48 | -10.47 | -10.38 | -15.05 | -22.56 |
| Price-to-Earnings Growth (PEG) Ratio | 5.08 | -1.26 | 2.08 | -0.35 | 0.00 |
| Enterprise Value Multiple | -33.41 | -5.88 | -8.88 | -10.71 | -18.43 |
| Enterprise Value | 14.40B | 2.37B | 2.89B | 3.11B | 3.28B |
| EV to EBITDA | -33.41 | -5.88 | -8.88 | -10.71 | -18.43 |
| EV to Sales | 0.00 | 0.00 | 89.66 | 0.00 | 468.81 |
| EV to Free Cash Flow | -38.15 | -6.54 | -8.68 | -11.16 | -18.88 |
| EV to Operating Cash Flow | -40.89 | -6.64 | -9.72 | -11.25 | -19.44 |
| Tangible Book Value Per Share | 14.91 | 21.51 | 12.04 | 20.77 | 11.45 |
| Shareholders’ Equity Per Share | 14.95 | 21.55 | 12.11 | 20.87 | 11.57 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.50 | 0.00 | 0.14 |
| Net Income Per Share | -5.23 | -5.61 | -5.24 | -5.48 | -3.89 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 10.44 | 0.00 | 24.85 |
| SG&A to Revenue | 0.00 | 0.00 | 1.34 | 0.00 | 2.85 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.77 | 0.00 | 0.42 |
| Income Quality | 0.79 | 0.85 | 0.88 | 0.96 | 0.90 |
Currency in TWD
